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Podocyte is a terminally committed cell in G1 arrest of cell
cycle, and is unable to overcome G1/S transition phase in
children with minimal change disease (MCD) and classic
focal segmental glomerulosclerosis (FSGS), in contrast to
dysregulated proliferative phenotype of idiopathic
collapsing glomerulopathy (CGN) in adults. Forty-two kidney
biopsies, MCD (14), FSGS (12), CGN (4), and normal (CON)
(12), were evaluated by immunohistochemistry using dual
staining for expression of p27, p21, and p57, and cyclins D
and A, in podocytes of children with CGN. On light
microscopy, all podocytes expressed p27, whereas p21 and
p57 expression was seen in a portion of podocytes in normal
kidney biopsies. Cyclin D was expressed in a small
percentage of podocytes. Cyclin A expression was absent in
normal biopsies. The staining for p27 decreased
significantly, in order, from normal (100%) to MCD (45.8%)
to CGN (24.2%) to FSGS (16.6%). p21 staining was
significantly decreased from normal (69.8%) to CGN (15.5%)
to MCD (2.2%) to FSGS (0.6%), and the difference between
CGN and MCD and FSGS was also significant. There was no
significant difference in staining of p57. Cyclin D staining
was significantly increased in CGN (26.8%) compared to
normal (7.2%), MCD (1.6%), and FSGS (0.0%), and the
difference between CGN and MCD and FSGS was also
significant. De novo cyclin A staining was only observed in
children with CGN. Thus, p27 and p21 but not p57 was
decreased in CGN, as in FSGS when compared to normal.
Both cyclins D and A staining were increased in CGN. The
staining pattern in CGN would suggest that podocyte is able
to overcome G1/S transition phase, and has a proliferative
phenotype. We propose, based on the significant contrast
observed in podocytes injury response between CGN
(proliferative) and classic FSGS (non-proliferative), that CGN
not be considered as a morphological variant of FSGS.
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The cell-cycle process is a highly organized process that
allows the cell to proliferate under both physiological and
pathological conditions. The process ensures that DNA
replication occurs only once and that the DNA replication
is completed before mitosis occurs in each cycle.1–3 This
highly organized cell-cycle process is regulated by a number
of cell-cycle regulatory proteins: (a) positive cell-cycle
regulatory proteins, such as ‘cyclins’ and ‘cyclin-dependent
kinase (CDK)’, which aid in the progression and completion
of cell cycle and (b) negative cell-cycle regulatory proteins,
‘cyclin kinase inhibitors’, which inhibit cell-cycle process.
Cells can also exit from cell cycle at any phase by undergoing
apoptosis (cell death), senescence (permanently growth
arrested cells), terminally committed specialized cells (cells
can proliferate under appropriate stimuli), or become
uncontrolled as in neoplasia.3 Mature podocytes (or visceral
glomerular epithelial cells) in the glomerulus are regarded as
terminally committed specialized cells that normally express
negative cell-cycle regulatory proteins p27, p21, and p57,
and positive cell-cycle regulatory proteins cyclin D but not
cyclin A, cyclin B1, or Ki-67.4,5
The characteristic findings in idiopathic nephrotic syn-
drome of childhood in podocytes are effacement of foot
processes, apical displacement of slit diaphragms, and
detachment from glomerular basement membrane.6–8 Our
findings from earlier studies have led us to propose that
podocyte injury clinically manifests as proteinuria and, at the
molecular level, podocyte proteins, such as synaptopodin,
glomerular epithelial protein 1 (GLEPP-1), and nephrin,
become disorganized. We showed a decrease in synapto-
podin, GLEPP-1, and nephrin expression in children with
minimal change disease (MCD) and focal segmental
glomerulosclerosis (FSGS).9,10 The common disease entities
found on renal biopsy in idiopathic nephrotic syndrome of
childhood include MCD, diffuse mesangial hypercellularity
(DMH), and FSGS, which together constitute B90% of
idiopathic nephrotic syndrome of childhood.11 FSGS is
classified into the following major categories: classic FSGS
(also known as FSGS, not otherwise specified), tip lesion
variant of FSGS, cellular variant of FSGS, and collapsing
variant of FSGS. Based on morphological grounds, the
distinction between the cellular and collapsing variants of
FSGS can be extremely difficult. In the cellular variant of
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FSGS, hyperplastic podocytes form a pseudocrescent without
attachment to Bowman’s capsule. Collapsing FSGS is
characterized by focal segmental or global glomerular
capillary collapse, with wrinkling and folding of basement
membrane, and with overlying hyperplasia and hypertrophy
of podocytes. Both the cellular and collapsing variants of
FSGS present with severe proteinuria, hypoalbuminemia,
higher serum creatinine levels at presentation, shorter time
course from presentation to biopsy, and progression to
end-stage renal disease.12
The podocyte is a unique glomerular cell because its
growth response to injury differs from the mesangial or
endothelial cell by virtue of its apparent inability to
proliferate.3 This raises the question of how a podocyte
responds to injury. In adult subjects with cellular and
collapsing variants of FSGS and with HIV-associated
nephropathy (HIVAN), Shankland et al.13 found decreased
p27 and p57 expression and de novo expression for p21 in
podocytes. In collapsing FSGS, Barisoni et al.14 reported a
decrease in p27, p57, and cyclin D1 expression along with the
expression for cyclin A and Ki-67 in podocytes. We found
that podocytes in children with MCD, DMH, and classic
FSGS downregulate the expression of cyclin kinase inhibitors
such as p21 and p27 but not p57, and do not upregulate
cyclins D and A that are needed to overcome the G1/S
transition and to move the cell forward in the cell cycle.4
Thus, the podocyte remains trapped in the G1 arrest phase
and has a non-proliferative phenotype, in contrast to the
dysregulated proliferative podocyte phenotype seen in adults
with cellular and collapsing variants of FSGS.13,14 In the
current study, we evaluated the expression of cell-cycle
regulatory proteins p27, p57, p21, and cyclins D and A in
podocytes from children with idiopathic collapsing glomerulo-
pathy (CGN). We found that the podocyte injury response
in CGN in children is consistent with a proliferative
phenotype, in contrast to children with MCD and classic
FSGS. This raises the question as to whether CGN should be
considered a separate disease entity rather than a morpho-
logic variant of FSGS.
RESULTS
The mean7s.d. for age in years for normal (8.475.3) was
not significantly different from CGN (10.777.0, p¼ 0.38),
MCD (5.473.2, p¼ 0.09), or FSGS (9.174.0, p¼ 0.73).
Children with MCD were younger than children with CGN
(p¼ 0.045) and FSGS (p¼ 0.047). The kidney biopsies in
children with proteinuria were performed for the evaluation
of associated hematuria in five (16.7%), steroid-sensitive
frequently relapsing/steroid-dependent nephrotic syndrome
in 12 (40%), and steroid-resistant nephrotic syndrome in 13
(43.3%). The subjects included 19 boys and 11 girls. There
were 21 Caucasian, six African-American, and three other
race children in the study. In the control group, there were six
boys and six girls, of which 11 were Caucasian and one
African-American.
The total number of glomeruli evaluated in each section
was 25.6717.4 (range 5–67) for control, 20.3713.7 (range
5–50) for MCD, 19.7715.3 (range 6–52) for FSGS, and
11.074.1 (range 5–14) for CGN. The total podocyte count
per glomerulus for normal (22.772.9) was not different from
MCD (19.673.1, p¼ 0.1) but was decreased in FSGS
(17.373.5, p¼ 0.002), and CGN (13.774.3, pp0.001).
Table 1 summarizes the results for the expression of cell-
cycle regulatory proteins p27, p21, p57, and cyclins D and A.
By light microscopical examination, all podocytes within all
glomeruli expressed p27 in normal biopsies. The percent of
positive glomeruli and podocytes expressing p27 decreased in
biopsies from CGN, MCD, and FSGS (Table 1 and Figure 1).
The decrease in p27 expression in podocytes reached
statistical difference between normal and CGN as well as
MCD and FSGS (Table 1). There was no statistical difference
between the expression in CGN and MCD or FSGS (Table 1).
Table 1 | Expression of p27, p21, p57, and cyclin D in podocytes of normal and children with CGN, MCD, and FSGS.
Percent-positive glomeruli Net percent-positive podocytes
Normal (n=12) CGN (n=4) MCD (n=14) FSGS (n=12) Normal (n=12) CGN (n=4) MCD (n=14) FSGS (n=12)
p27 100.070.0 76.5737.4 66.9739.4 39.7735.2 100.070.0 24.2719.3 45.8731.5 16.6718.8
Normal versus (p-value) — 0.579 0.054 o0.001 — o0.001 o0.001 o0.001
CGN versus (p-value) — — 0.95 0.202 — — 0.310 0.931
p21 100.070.0 58.6739.4 9.2715.1 2.876.6 69.879.9 15.5718.4 2.274.3 0.671.6
Normal versus (p-value) — 0.001 o0.001 o0.001 — o0.001 o0.001 o0.001
CGN versus (p-value) — — o0.001 o0.001 — — 0.019 0.009
p57 100.070.0 76.5737.4 99.072.0 96.377.0 55.7714.3 55.5726.6 44.7718.7 45.0718.1
Normal versus (p-value) — 0.006 0.997 0.869 — 1.000 0.453 0.506
CGN versus (p-value) — — 0.007 0.023 — — 0.728 0.754
Cyclin D 36.2737.5 76.5737.4 8.3714.8 0.070.0 7.279.4 26.8713.3 1.673.6 0.070.0
Normal versus (p-value) — 0.029 0.035 0.005 — o0.001 0.187 0.065
CGN versus (p-value) — — o0.001 o0.001 — — o0.001 o0.001
Cyclin A 0.070.0 43.6728.3 0.070.0 0.070.0 0.070.0 10.376.7 0.070.0 0.070.0
Normal versus (p-value) — o0.001 1.000 1.000 — o0.001 1.000 1.000
CGN versus (p-value) — — o0.001 o0.001 — — o0.001 o0.001
Abbreviations: CGN, collapsing glomerulopathy; FSGS, focal segmental glomerulosclerosis; MCD, minimal change disease)
The results are expressed as mean7s.d
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Thus, p27 expression in podocytes decreased in biopsies with
CGN when compared to normal, but was similar to that seen
in biopsies from MCD and FSGS.
In normal biopsies, podocytes expressing p21 were
observed in all glomeruli; however, in a given glomerulus
not all podocytes expressed p21 (Table 1 and Figure 1). The
percent of positive glomeruli and positive podocytes expres-
sing p21 were significantly reduced in biopsies from CGN,
MCD, and FSGS when compared to normal and this decrease
was statistically significant (Table 1 and Figure 1). The p21
expression, although decreased, was better preserved in
biopsy from CGN where it was overall higher than in
biopsies from MCD and FSGS (Table 1).
In normal biopsies, all glomeruli had podocytes that
expressed p57 protein, but like p21, not all podocytes in the
glomeruli expressed p57 (Table 1 and Figure 1). Although the
number of glomeruli-expressing p57 was decreased in CGN,
there was no statistically significant difference in the
expression within podocytes in normal versus CGN, MCD,
and FSGS (Table 1).
By light microscopy, cyclin D was predominantly
observed in endothelial and mesangial cells in the glomeruli,
although a small percentage of glomeruli and podocytes did
express cyclin D in normal biopsies (Table 1 and Figure 1).
Cyclin D expression was increased in CGN, whereas it
decreased in biopsies from MCD and FSGS when compared
p27 Normal
p21 Normal
p57 Normal
Cyclin D Normal
Cyclin A Normal
p27 MCD
p57 MCD
Cyclin D MCD
Cyclin A MCD
p21 MCD
p27 FSGS
p57 FSGS
Cyclin D FSGS
Cyclin A FSGS
p21 FSGS
p27 CGN
p57 CGN
Cyclin D CGN
Cyclin A CGN
p21 CGN
Figure 1 | The photomicrograph shows the staining of p27, p21, p57, and cyclins D and A in podocytes of normal and children with
MCD, classic FSGS, and CGN in kidney tissue. The podocyte is identified by WT-1 staining (stained red with Vector red) and the cell-cycle
regulatory protein is stained brown-black with diaminobenzidine with 3% cobalt. Only podocytes that showed homogeneous staining for
cell-cycle regulatory proteins above the background were accepted as positive staining. The staining for p27 decreased in order from
normal to MCD to CGN to FSGS. p21 staining was markedly decreased in children with MCD, CGN, or FSGS compared to normal. p57 staining
remained unchanged between normal, MCD, FSGS, and CGN. Cyclin D expression was increased in CGN and similar between normal, MCD,
and FSGS. Cyclin A expression was only observed in CGN and absent in normal, MCD, or FSGS.
Kidney International (2006) 70, 529–535 531
T Srivastava et al.: Cell-cycle proteins in collapsing glomerulopathy o r i g i n a l a r t i c l e
to normal. There was a significant increase in cyclin D
expression in podocytes from CGN when compared to
normal, MCD, and FSGS. There was no significant diffe-
rence in cyclin D expression between normal and biopsies
from MCD and FSGS. Thus, the staining for cyclin D was
markedly increased in CGN as compared to normal, MCD,
and FSGS.
Light microscopical evaluation for cyclin A showed that it
was not expressed in the podocytes of normal, MCD, and
FSGS (Table 1 and Figure 1). Cyclin A expression was only
observed in biopsies from CGN.
In summary, the normal podocyte, a terminally com-
mitted cell, shows expression of cyclin kinase inhibitors p27,
p21, and p57, as well as cyclin D but not cyclin A. In MCD
and FSGS, following podocyte injury, the podocyte remains
trapped in the G1/S cell-cycle phase, as manifested by
decreased staining of cyclin kinase inhibitors p27 and p21,
but not p57, and no increased staining of cyclins D and A. On
the other hand, podocytes following injury in CGN are able
to overcome the G1/S cell-cycle restriction step, and can
proliferate, as observed by decreased staining of p27 and p21,
but not p57, and increased staining of cyclins D and A
(Figure 2).
DISCUSSION
In recent years, cell-cycle regulatory proteins have become
an area of intense research in order to understand the
changes that occur in various renal diseases. The roles of
these proteins in renal diseases have been addressed in
several reviews.1–3 In adult subjects with cellular or
collapsing variant of FSGS and HIVAN, podocytes were
observed to have decreased expression of p27, p57, and
cyclin D, and increased expression of p21, cyclin A, and
Ki-67, suggesting a dysregulated podocyte phenotype
characterized by de-differentiation and proliferation.13,14 In
contrast, Nagata et al.19 has contested that the proliferating
epithelial cells in collapsing FSGS are not podocytes but
instead are parietal epithelial cells. To overcome the issue of
podocyte versus parietal epithelial cell type, we identified
podocyte by WT-1 expression, based on the observation of
Mundlos et al.18 that WT-1 protein is exclusively expressed
in podocytes. This technique then allowed us to study cell-
cycle regulatory proteins expressed solely in podocytes by
excluding other resident cells of the glomerulus. The
expression pattern of the cell-cycle regulatory proteins
p27, p21, p57, and cyclins D and A were similar from
control tissue (normal) obtained from children who had
normal renal biopsies for loin pain-hematuria syndrome
and from nephrectomy specimens from children with WT
(unpublished observation), hence we used them as a single
control group.
We had observed that podocytes in children with MCD,
DMH, and classic FSGS showed decreased expression of
cyclin kinase inhibitors such as p21 and p27, but not p57,
and do not show increased expression of cyclins D and A that
are needed to overcome the G1/S transition in order to move
the cell forward in the cell-cycle process.4 Therefore, the
podocyte remains trapped in the G1 arrest phase and has a
non-proliferative phenotype. This dysregulated podocyte
phenotype observed in classic FSGS was different than that
described in adults with either cellular or collapsing variant of
FSGS.13,14 Hence, we studied the cell-cycle regulatory
proteins p27, p57, p21, and cyclins D and A expression in
podocytes in children with CGN to evaluate if the podocyte
injury response is similar or different in CGN from classic
FSGS.
p27 is believed to play a role in differentiation of cells,
maintain podocytes in quiescence by cell-cycle arrest in G1
phase, and to modulate apoptosis and cell-cycle exit response
to antimitogenic cues.5,20 In our earlier study, we observed a
significant decrease in p27 expression in podocytes in
children with idiopathic nephrotic syndrome, decreasing in
order from normal to MCD to DMH to FSGS.4 Similarly,
in adults, p27 is reported to be decreased in cellular and
collapsing variant of FSGS and HIVAN.13 p27 levels are
generally high in most quiescent cells but decrease during
proliferation.21 Thus, it was not surprising to find decreased
p27 expression in CGN in the current study as such
a decrease would be anticipated if the podocyte is to
de-differentiate and proliferate.
Cyclins A, B
Cyclin D
Cyclin D
Cyclin A
Cyclin A
Phenotype Terminally 
differentiated
Non- 
proliferative
Normal Classic 
FSGS
CGN
Cyclin E
Terminal differentiation
M
S
R
G2/M checkpoint
G1/S checkpoint
G0
G1
G2
CKI–p21, p27, p57
CKI–p21, p27, p57 CKI–p21, p27, p57
CKI–p15, p16, p18, p19
p21, p27, p57
p27
p21
p57
Present
Present
Present
Present
Absent Absent
Present Present
Present
Decreased
Decreased
Decreased
Decreased
Increased
Decreased
Proliferative
Figure 2 | Schematic diagram of cell-cycle phases, checkpoints,
and restriction point (R) in a eukaryotic cell showing major cyclin
and cyclin kinase inhibitors (CKI). The cell-cycle arrest can occur at
G1/S or G2/M checkpoint. The podocyte is a terminally differentiated
cell that normally expresses low level of cyclin D and CKIs’ p27, p21,
and p57. The podocyte in MCD and FSGS remain trapped in G1/S
phase as suggested by a decrease in CKIs’ p27 and p21, but not p57,
and no increase in cyclins D or A. On the other hand, podocyte in
CGN shows a decrease in CKIs’ p27 and p21, but not p57, and
increase in cyclins D and A.
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The p21 protein plays an important role at the G1
checkpoint.22 p21 is rapidly induced in response to
physiological and chemical inducers of differentiation, and
the p21 gene is a candidate gene linking differentiation
signals to G1 arrest in multiple cell lines.
23 In our earlier
study, we had shown p21 to be expressed in normal
podocytes and to decrease significantly in children with
MCD, DMH, and FSGS.4 Interestingly, p21 exists predomi-
nantly as quaternary complexes of p21/proliferating cell
nuclear antigen/cyclin/CDK, which can be both catalytically
active and inactive depending on the stoichiometric ratio of
p21 to the kinase subunits.24,25 Thus, at a low stoichiometric
ratio, p21 facilitates kinase complex assembly and promotes
kinase activation. Therefore, it was not unexpected to find a
decrease p21 expression in our study, if the podocyte is to de-
differentiate and proliferate in CGN. Our finding is in
contrast to Shankland et al.13 who did not detect p21 in
normal tissue but instead found de novo expression of p21 in
adults with cellular and collapsing variants of FSGS and
HIVAN. The antibody used in the current study is clone 187,
produced by immunization with full length p21 of human
origin. The antibody used by Shankland et al.13 was from
clone SX 118, which is raised against a purified recombinant
human p21-GST fusion protein and only recognizes the
proliferating cell nuclear antigen-binding domain of p21.
Based on what we know about the structure of p21 and the
epitope recognition sites of the antibodies used in the
two studies, we speculate that in CGN, as the podocyte
de-differentiates and develops a proliferative phenotype, the
cryptic proliferating cell nuclear antigen-binding domain of
p21 is freed up from the quaternary complex, which is
recognized by the antibody. This would make the discrepant
findings of p21 expression observed in our study and that
observed by Shankland et al.13 congruent.
p57 plays a role in the differentiation of cells and
overexpression of p57 arrests the cell in G1 phase.
26,27 p57
is reported to be decreased in cellular and collapsing variant
of FSGS and HIVAN.13,14 We had not observed any difference
in p57 expression in podocytes from normal biopsies or those
with MCD, DMH, or FSGS.4 There was a decrease in the
number of glomeruli expressing p57, but the net podocyte
expression of p57 was not significantly different between
CGN and normal, MCD, and FSGS. p57 is believed to be a
tumor suppressor protein based on its association with
numerous malignancies and has a reduced affinity for cyclin
D–CDK6 complex compared to p27.27 Our findings suggest
that p57 may play a role in podocyte differentiation, but it
may not be a critical player in podocyte proliferation.
Cyclin D is required for cell proliferation and G1/S
transition. It works through inactivation of the retinoblastoma
protein.3 In our study, cyclin D was predominantly
expressed in endothelial and mesangial cells of the glomeru-
lus in normal biopsies, MCD and FSGS. In our earlier study,
we did not observe any difference in cyclin D expression in
podocytes from normal biopsies and those with MCD, DMH,
and FSGS.4 Cyclin D was markedly upregulated in podocytes
in CGN. There was almost a twofold increase in the number
of glomeruli expressing cyclin D and a fourfold increase in
podocytes expressing cyclin D. Cyclin D is important for
G0/G1 and G1/S transition in the cell-cycle process. An
increase in cyclin D levels would support a proliferative
phenotype of podocytes in CGN in contrast to a non-
proliferative phenotype in classic FSGS.
Cyclin A increases in late G1, peaks in both S and G2
phases, and is required for the onset of DNA synthesis.3 In
our earlier study, we did not observe any expression of cyclin
A in podocytes from normal biopsies and those with MCD,
DMH, and FSGS.4 In children with CGN, there was de novo
expression of cyclin A and this has also been previously
observed by Barisoni et al.14 in adults with collapsing and
cellular variants of FSGS and HIVAN. De novo expression of
cyclin A would support that the podocyte has crossed the G1/S
restriction point and moved to S and G2 phase of cell cycle.
This again supports a proliferative phenotype of podocytes
in CGN in contrast to a non-proliferative phenotype in
classic FSGS.
There is an ongoing debate in the literature whether it is
the parietal epithelial cell or the podocyte that is proliferating
in the cellular variant or collapsing variant of FSGS. In our
study, we used WT-1 as a surrogate podocyte marker; hence,
the cell-cycle regulatory proteins changes observed by us in
CGN are localized to podocytes, and not the parietal
epithelial cell (which lack WT-1 expression). The staining
pattern of increased cyclins D and A, and decreased staining
in p27 and p21 would support a proliferative phenotype for
the podocyte in CGN, in contrast to classic FSGS. In CGN,
there is the possibility of podocytes becoming de-differen-
tiated to the extent that they lose WT-1 staining or are
completely lost from the glomerulus. The observed pattern of
staining for cell-cycle regulatory proteins in podocytes
between CGN and classic FSGS are markedly different. In
CGN, we observed an increased staining of cyclin D and de
novo staining of cyclin A, which represent markers for cell-
cycle phase beyond G1/S in CGN, in contrast to the absent or
decreased staining for cyclins D and A in classic FSGS. Thus,
even if we underestimated the percentage of positive
podocytes because of the de-differentiated podocytes lacking
WT-1 staining, our results would still support that the
podocytes have a proliferative phenotype in CGN in contrast
to classic FSGS. If podocyte loss was responsible for the
quantitative differences in cell-cycle regulatory proteins in
CGN, then we should have seen a further decrease staining of
cell-cycle regulatory proteins in CGN. On the contrary, we
found increased staining of cyclin D, cyclin A, and p21 in
podocytes. In addition, the expression of p27 in CGN was
higher than in FSGS, which had a higher percentage of
positive podocyte count. Thus, loss of podocytes from the
glomerulus or de-differentiation of podocytes to the extent of
losing WT-1 staining should not alter the results significantly.
Could our observed quantitative differences in cell-cycle
regulatory proteins in CGN be age dependent or due to a
small sample size? With regard to age-dependent differences,
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there was no significant difference between the ages of the
normal group and children with CGN, MCD, and FSGS;
therefore, we cannot attribute the observed changes in cell-
cycle regulatory proteins in podocytes to the age of the child.
CGN is a rare entity in pediatric age group. In our own series
of 34 children with FSGS from 1984 to 1995 seen in the
midwest (USA), we did not find a single child with either
cellular or collapsing variant of FSGS.11 This study is an
extension of our earlier work carried out in collaboration
with The University of North Carolina at Chapel Hill who
had previously described a small case series of children with
CGN, and provided these clinical samples.28 Although the
sample size is small (n¼ 4), the robust qualitative changes
seen in both cyclins D and A expression in podocytes support
our result of a de-differentiated and proliferative podocyte
phenotype. We can cautiously speculate that inclusion of a
larger sample size would likely not alter our conclusions.
There was no statistically significant difference between the
expression of podocyte cell-cycle regulatory proteins and
clinical response to steroids, nor was there a statistically
significant difference in the expression of cell-cycle regulatory
proteins between Caucasian and African-American children
(data not shown). The study does have its limitations owing
to a small sample size of CGN, use of archived human tissue,
and a semiquantitative analysis approach; however, despite
these limitations, the changes are sufficiently uniform to
justify our findings.
In conclusion, we observed p27, p57, and p21 to be
present in normal kidneys, which keeps the podocyte
differentiated and quiescent in G1 arrest. In MCD and classic
FSGS, we found podocytes to have decreased staining for p21
and p27, but not p57, and failure to have increased staining
for cyclins D and A (marker of ‘S’ and ‘G2’ phase) that are
needed for proliferation. Thus, the podocyte remains trapped
in G1 arrest phase. In contrast, in CGN, there is decreased
staining of p27 and p21, but not p57, and increased staining
for cyclins D and A to support a proliferative podocyte
phenotype.
Our current study was a follow-up on our earlier study
where we had failed to demonstrate a proliferative phenotype
in children with classic FSGS compared to reports in adults of
a de-differentiated and proliferative podocyte phenotype in
cellular and/or collapsing FSGS. We had speculated that the
pathogenic mechanisms that underlie classic FSGS are
different from CGN. In the current study, we demonstrated
that proliferation is a characteristic feature of the podocyte in
CGN, unlike the non-proliferative phenotype of classic FSGS.
Although both classic FSGS and CGN result from a yet
undefined immunological podocyte injury, the cellular
response of podocytes to the injury is strikingly different in
CGN and classic FSGS. Therefore, this raises the question as
to whether CGN should be considered as a continuum of
FSGS with a more severe podocyte injury. Given the distinct
differences in the podocyte response of the two disease
entities, we would propose that CGN be considered as a
separate podocyte disease (podocytopathy) rather than a
morphological variant of FSGS.
MATERIALS AND METHODS
Kidney biopsies from children were included in the study only if the
histology was consistent with MCD or FSGS as described by the
International Study of Kidney Disease in Children15 and CGN as
described by Valeri et al.16 and Detwiler et al.17 Control tissue
(normal) was obtained from children who had a normal renal
biopsy following evaluation for loin pain-hematuria syndrome
(n¼ 7) and from nephrectomy specimens from children with
Wilm’s tumor (n¼ 5). A total of 42 kidney biopsies were
investigated: MCD (n¼ 14), FSGS (n¼ 12), CGN (n¼ 4), and
normal (n¼ 12). The biopsy tissue for CGN came from The
University of North Carolina at Chapel Hill while the rest were from
Children’s Mercy Hospital. Patient demographics including age, sex,
and race were noted at the time of biopsy. The sections were
examined by immunohistochemistry using a dual staining method
as described by Srivastava et al.4 with appropriate negative and
positive controls (Table 2).
Kidney biopsies stained for Wilm’s tumor-1 (WT-1) and one of
the cell-cycle regulatory proteins were first examined by light
microscopy. Podocytes were identified in the biopsies by WT-1
staining as it is exclusively expressed in the podocytes in glomeruli.18
On light microscopy, a qualitative evaluation of each glomerulus
was carried out for the expression of: (1) WT-1 and each of the cell-
cycle regulatory proteins (i.e. podocytes expressing the protein
under study), (2) WT-1 protein only (i.e. podocytes not expressing
the protein under study), and (3) only the cell-cycle regulatory
Table 2 | Antibodies used in the dual staining immunohistochemistry
Antibody to Source Company Dilution Universal Dako’s LSAB+ with Chromogen
WT-1 (M3561) Mouse monoclonal Dako Corp., Carpinteria,
CA, USA
1:100 Streptavidin–biotin conjugated
to alkaline phosphatase
Vector red
p27 (sc-1641) Mouse monoclonal Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA
1:50 Streptavidin–biotin conjugated
to horseradish peroxidase
Diaminobenzidine
with 3% cobalt
P21 (sc-817) Mouse monoclonal Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA
1:100 Streptavidin–biotin conjugated
to horseradish peroxidase
Diaminobenzidine
with 3% cobalt
p57 (sc-1040G) Goat polyclonal Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA
1:50 Streptavidin–biotin conjugated
to horseradish peroxidase
Diaminobenzidine
with 3% cobalt
Cyclin D1 (sc-8396) Mouse monoclonal Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA
1:50 Streptavidin–biotin conjugated
to horseradish peroxidase
Diaminobenzidine
with 3% cobalt
Cyclin A (sc-751) Rabbit polyclonal Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA
1:100 Streptavidin–biotin conjugated
to horseradish peroxidase
Diaminobenzidine
with 3% cobalt
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protein but not WT-1 (non-podocyte glomerular cells expressing the
protein under study). Following an initial qualitative assessment, a
semiquantitative analysis for cell-cycle regulatory protein expression
was performed. First, the percentage of glomeruli that stained
positive for cell-cycle regulatory protein in the biopsy section was
obtained. Next, in glomeruli that stained positive for cell-cycle
regulatory protein under study, the percentage of podocytes that
express the cell-cycle regulatory protein was obtained. The product
of the above two values gave the proportion of total podocytes that
expressed the cell-cycle regulatory protein in each section, and are
shown as net percent-positive podocytes. Statistical analysis was
performed using univariate analysis of variance followed by Tukey’s
honestly significant difference test.
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